Atlas Trials

Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

RecordFirmDate
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy (NCT02694822)Agenus Inc.2016-04-01

Track Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies automatically

Every clearance here is in the API, with alerts when new ones post.